Startseite Lebenswissenschaften The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction

  • , , und
Veröffentlicht/Copyright: 26. Juni 2006
Biological Chemistry
Aus der Zeitschrift Band 387 Heft 6

Abstract

Tissue kallikrein (hK1) cleaves low-molecular-weight kininogen to produce kinin peptide, which binds to kinin receptors and triggers a wide spectrum of biological effects. Tissue kallikrein levels are reduced in humans and in animal models with hypertension, cardiovascular and renal diseases. Transgenic mice or rats over-expressing human tissue kallikrein or kinin B2 receptor are permanently hypotensive, and somatic kallikrein gene delivery reduces blood pressure in several hypertensive rat models. Moreover, kallikrein gene delivery or kallikrein protein infusion can directly improve cardiac, renal and neurological function without blood pressure reduction. Kallikrein has pleiotropic effects in inhibiting apoptosis, inflammation, proliferation, hypertrophy and fibrosis, and promoting angiogenesis and neurogenesis in different experimental animal models. Kallikrein's effects can be blocked by kinin B2 receptor antagonists. Mechanistically, tissue kallikrein/kinin leads to increased nitric oxide levels and Akt activation, and reduced reactive oxygen species formation, TGF-β1 expression, MAPK and nuclear factor-κB activation. Our studies indicate that tissue kallikrein, through the kinin B2 receptor and nitric oxide formation, can protect against oxidative damage in cardiovascular and renal diseases and ischemic stroke. These novel findings suggest that kallikrein/kinin may serve as new drug targets for the prevention and treatment of heart failure, renal disease and stroke in humans.

:

Corresponding author

References

Abelous, J. and Bardier, E. (1909). Les substances hypotensive de l'urine humaine normale. C.R. Soc. Biol. (Paris)66, 511–512.Suche in Google Scholar

Agata, J., Chao, L., and Chao, J. (2002). Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension40, 653–659.10.1161/01.HYP.0000036035.41122.99Suche in Google Scholar

Araujo, R.C., Kettritz, R., Fichtner, I., Paiva, A.C., Pesquero, J.B., and Bader, M. (2001). Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol. Chem.382, 91–95.10.1515/BC.2001.014Suche in Google Scholar

Ashley, P.L. and MacDonald, R.J. (1985). Tissue-specific expression of kallikrein-related genes in the rat. Biochemistry24, 4520–4527.10.1021/bi00338a006Suche in Google Scholar

Azizi, M., Boutouyrie, P., Bissery, A., Agharazii, M., Verbeke, F., Stern, N., Bura-Riviere, A., Laurent, S., Alhenc-Gelas, F., and Jeunemaitre, X. (2005). Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest.115, 780–787.10.1172/JCI200523669Suche in Google Scholar

Bellomo, M., Adamo, E.B., Deodato, B., Catania, M.A., Mannucci, C., Marini, H., Marciano, M.C., Marini, R., Sapienza, S., Giacca, M., et al. (2003). Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil. Pharmacol. Res.48, 309–317.10.1016/S1043-6618(03)00128-2Suche in Google Scholar

Berry, T.D., Hasstedt, S.J., Hunt, S.C., Wu, L.L., Smith, J.B., Ash, K.O., Kuida, H., and Williams, R.R. (1989). A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension13, 3–8.10.1161/01.HYP.13.1.3Suche in Google Scholar PubMed

Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev.44, 1–80.Suche in Google Scholar

Bledsoe, G., Chao, L., and Chao, J. (2003). Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol.285, H1479–1488.10.1152/ajpheart.01129.2002Suche in Google Scholar PubMed

Bledsoe, G., Crickman, S., Mao, J., Xia, C.F., Murakami, H., Chao, L., and Chao, J. (2006). Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol. Dial. Transplant.21, 624–633.10.1093/ndt/gfi225Suche in Google Scholar PubMed

Bouhnik, J., Richoux, J.P., Huang, H., Savoie, F., Baussant, T., Alhenc-Gelas, F., and Corvol, P. (1992). Hypertension in Dahl salt-sensitive rats: biochemical and immunohistochemical studies. Clin. Sci.83, 13–22.10.1042/cs0830013Suche in Google Scholar PubMed

Braun, C., Kleeman, T., Hilgenfeldt, U., Riester, U., Rohmeiss, P., and van der Woude, F.J. (2002). Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat. Kidney Int.61, 2149–2156.10.1046/j.1523-1755.2002.00385.xSuche in Google Scholar PubMed

Calixto, J.B., Carbrini, D.A., Ferreira, J., and Campos, M.M. (2000). Kinins in pain and inflammation. Pain87, 1–5.10.1016/S0304-3959(00)00335-3Suche in Google Scholar

Cardin, A.D., Witt, K.R., Chao, J., Margolius, H.S., Donaldson, V.H., and Jackson, R.L. (1984). Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins. J. Biol. Chem.259, 8522–8528.10.1016/S0021-9258(17)39761-2Suche in Google Scholar

Chao, J. and Chao, L. (1996). Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension27, 491–494.10.1161/01.HYP.27.3.491Suche in Google Scholar

Chao, J. and Margolius, H.S. (1983). Differential effects of testosterone, thyroxine and cortisol on rat submandibular gland and renal kallikrein. Endocrinology113, 2221–2225.10.1210/endo-113-6-2221Suche in Google Scholar

Chao, J., Tillman, D.M., Wang, M., Margolius, H.S., and Chao, L. (1986). Identification of a new tissue kallikrein-binding protein. Biochem. J.239, 325–331.10.1042/bj2390325Suche in Google Scholar

Chao, J., Chao, L., Swain, C., Tsai, J., and Margolius, H.S. (1987). Tissue kallikrein in rat brain and pituitary: regional distribution and estrogen induction in the anterior pituitary. Endocrinology120, 475–482.10.1210/endo-120-2-475Suche in Google Scholar

Chao, J., Chai, K.X., Chen, L.M., Xiong, W., Chao, S., Woodley-Miller, C., Wang, L., Lu, H.S., and Chao, L. (1990). Tissue kallikrein-binding protein: purification, characterization and distribution in normotensive and hypertensive rats. J. Biol. Chem.265, 16394–16401.10.1016/S0021-9258(17)46236-3Suche in Google Scholar

Chao, J., Jin, L., Chen, L.M., Chen, V.C., and Chao, L. (1996). Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum. Gene Ther.7, 901–911.10.1089/hum.1996.7.8-901Suche in Google Scholar PubMed

Chao, J., Stallone, J.N., Liang, Y.M., Chen, L.M., and Chao, L. (1997). Kallistatin is a potent new vasodilator. J. Clin. Invest.100, 11–17.10.1172/JCI119502Suche in Google Scholar PubMed PubMed Central

Chao, J., Zhang, J., Lin, K.F., and Chao, L. (1998a). Adenovirus-mediated kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum. Gene Ther.9, 1–31.10.1089/hum.1998.9.1-21Suche in Google Scholar PubMed

Chao, J., Zhang, J.J., Lin, K.F., and Chao, L. (1998b). Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int.54, 1250–1260.10.1046/j.1523-1755.1998.00104.xSuche in Google Scholar

Chao, J., Miao, R.Q., Chen, V., Chen, L.M., and Chao, L. (2001). Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol. Chem.382, 15–21.10.1515/BC.2001.003Suche in Google Scholar

Clements, J.A. (1989). The glandular kallikrein family of enzyme: tissue specific expression and hormonal regulation. Endocr. Rev.10, 393–419.10.1210/edrv-10-4-393Suche in Google Scholar

Clements, J.A., Fuller, P.J. McNally, M., Nikolaidis, I., and Funder, J.W. (1986). Estrogen regulation of kallikrein gene expression in the rat anterior pituitary. Endocrinology119, 268–273.10.1210/endo-119-1-268Suche in Google Scholar

Colman, R.W., Wachtfogel, Y.T., Kucich, U., Weinbaum, G., Hahn, S., Pixley, R.A., Scott, C.F., De Agostini, A., Burger, D., and Schapira, M. (1985). Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood65, 311–318.10.1182/blood.V65.2.311.311Suche in Google Scholar

Couture, R., Harrisson, M., Vianna, R.M., and Cloutier, F. (2001). Kinin receptors in pain and inflammation. Eur. J. Pharmacol.429, 161–176.10.1016/S0014-2999(01)01318-8Suche in Google Scholar

Currie, M.G., Gelllen, D.M., Chao, J., Margolius, H.S., and Needleman, P. (1984). Kallikrein activation of a high molecular weight atrial peptide. Biochem. Biophys. Res. Commun.120, 461–466.10.1016/0006-291X(84)91276-2Suche in Google Scholar

Dai, C., Yang, J., Bastacky, S., Xia, J., Li, Y., and Liu, Y. (2004). Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J. Am. Soc. Nephrol.15, 2637–2647.10.1097/01.ASN.0000139479.09658.EESuche in Google Scholar PubMed

Derkx, F.H.M., Tan-Tjiong, H.L., Man In't Veld, A.J., Schalekamp, M.P.A., and Schalekamp, M.A.H. (1979). Activation of inactive plasma renin by tissue kallikrein. J. Clin. Endocrinol. Metab.49, 765–769.10.1210/jcem-49-5-765Suche in Google Scholar PubMed

Diamandis, E.P., Yousef, G.M., Clements, J., Ashworth, L.K., Yoshida, S., Egelrud, T., Nelson, P.S., Shiosaka, S., Little, S., Lilja, H., et al. (2000). New nomenclature for the human tissue kallikrein gene family. Clin. Chem.46, 1855–1858.10.1093/clinchem/46.11.1855Suche in Google Scholar

Dobrzynski, E., Yoshida, H., Chao, J., and Chao, L. (1999). Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology44, 57–65.10.1016/S0162-3109(99)00121-6Suche in Google Scholar

Elliot, R. and Nuzum, F. (1934). Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology18, 462–474.10.1210/endo-18-4-462Suche in Google Scholar

Emanueli, C., Maestri, R., Corradi, D., Marchione, R., Minasi, A., Tozzi, M.G., Salis, M.B., Straino, S., Capogrossi, M.C., Olivetti, G., and Madeddu, P. (1999). Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation100, 2359–2365.10.1161/01.CIR.100.23.2359Suche in Google Scholar

Emanueli, C., Salis, M.B., Chao, J., Chao, L., Agata, J., Lin, K.F., Munao, A., Straino, S., Minasi, A., Capogrossi, M.C., and Madeddu, P. (2000). Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler. Thromb. Vasc. Biol.20, 1459–1466.10.1161/01.ATV.20.6.1459Suche in Google Scholar

Emanueli, C., Minasi, A., Zacheo, A., Chao, J., Chao, L., Bonaria Salis, M., Straino, S., Tozzi, M.G., Smith, R., Gaspa, L., et al. (2001). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation103, 125–132.10.1161/01.CIR.103.1.125Suche in Google Scholar PubMed

Emanueli, C., Salis, M.B., Pinna, A., Stacca, T., Milia, A.F., Spano, A., Chao, J., Chao, L., Sciola, L., and Madeddu, P. (2002). Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation106, 993–999.10.1161/01.CIR.0000027104.33206.C8Suche in Google Scholar PubMed

Evans, B.A., Drinkwater, C.C., and Richards, R.I. (1987). Mouse glandular kallikrein genes. Structure and partial sequence analysis of the kallikrein gene locus. J. Biol. Chem.262, 8027–8034.Suche in Google Scholar

Farhy, R.D., Carretero, O.A., Ho, K.L., and Scicli, A.G. (1993). Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ. Res.72, 1202–1210.10.1161/01.RES.72.6.1202Suche in Google Scholar PubMed

Favaro, S., Baggio, B., Antonello, A., Zen, A., Cannella, G., Todesco, S., and Borsatti, A. (1975). Renal kallikrein content of spontaneously hypertensive rats. Clin. Sci. Mol. Med.49, 69–71.10.1042/cs0490069Suche in Google Scholar PubMed

Fisher, M. (2002). Developing therapy for acute ischemic stroke. Therapie57, 564–568.Suche in Google Scholar

Francis, S.C., Raizada, M.K., Mangi, A.A., Melo, L.G., Dzau, V.J., Vale, P.R., Isner, J.M., Losordo, D.W., Chao, J., Katovich, M.J., and Berecek, K.H. (2001) Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol. Genomics7, 79–94.10.1152/physiolgenomics.00073.2001Suche in Google Scholar PubMed

Frey, E.K. and Kraut, H. (1928). Ein neues Kreislaufhormon und seine Wirkung. Arch. Exp. Pathol. Pharmakol.133, 1.10.1007/BF01955578Suche in Google Scholar

Gavras, I. and Gavras, H. (1988). Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int.34, S60–S62.Suche in Google Scholar

Geller, R.G., Margolius, H.S., Pisano, J.J., and Keiser, H.R. (1975). Urinary kallikrein excretion in spontaneously hypertensive rats. Circ. Res.36, 103–106.10.1161/01.RES.36.6.103Suche in Google Scholar

Gerald, W.L., Chao, J., and Chao, L. (1986). Sex dimorphism and hormonal regulation of rat tissue kallikrein mRNA. Biochim. Biophys. Acta867, 16–23.10.1016/0167-4781(86)90024-2Suche in Google Scholar

Griol-Charhbili, V., Messadi-Laribi, E., Bascands, J.L., Heudes, D., Meneton, P., Giudicelli, J.F., Alhenc-Gelas, F., and Richer C. (2005). Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J.19, 1172–1174.10.1096/fj.04-3508fjeSuche in Google Scholar

Groger, M., Lebesgue, D., Pruneau, D., Relton, J., Kim, S.W., Nussberger, J., and Plesnila, N. (2005). Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab.25, 978–989.10.1038/sj.jcbfm.9600096Suche in Google Scholar

Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A., Ashworth, L.K., and Clements, J.A. (2000). Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem.275, 37397–37406.10.1074/jbc.M004525200Suche in Google Scholar

Hashimoto, N., Takeyoshi, I., Tsutsumi, H., Sunsoe, Y., Tokumine, M., Totsuka, O., Ohwada, S., Matsuomoto, K., and Morishita, Y. (2004). Effects of a bradykinin B2 receptor antagonist on ischemia-reperfusion injury in a canine lung transplantation model. J. Heart Lung Transplant23, 606–613.10.1016/S1053-2498(03)00297-3Suche in Google Scholar

Hirawa, N., Uehara, Y., Suzuki, T., Kawabata, Y., Numabe, A., Gomi, T., Ikeda, T., Kizuki, K., and Omata, M. (1999). Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2 receptor-mediated event. Nephron81, 183–193.10.1159/000045275Suche in Google Scholar PubMed

Huang, Z.G., Xue, D., Preston, E., Karbalai, H., and Buchan, A.M. (1999). Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia. Can. J. Neurol. Sci.26, 298–304.10.1017/S0317167100000421Suche in Google Scholar PubMed

Jaffa, A.A., Harvey, J.N., Sutherland, S.E., Margolius, H.S., and Mayfield, R.K. (1989). Renal kallikrein responses to dietary protein: a possible mediator of hyperfiltration. Kidney Int.36, 1003–1010.10.1038/ki.1989.294Suche in Google Scholar PubMed

Jaffa, A.A., Miller, D.H., Margolius, H.S., and Marfield, R.K. (1990). Regulation of renal kallikrein synthesis and activation by glucocorticoid. Kidney Int.38, 21–28.10.1038/ki.1990.188Suche in Google Scholar PubMed

Jin, L., Zhang, J.J., Chao, L., and Chao, J. (1997). Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum. Gene Ther.8, 1753–1761.10.1089/hum.1997.8.15-1753Suche in Google Scholar

Jin, L., Chao, L., and Chao, J. (1999). Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in spontaneously hypertensive rats. Am. J. Physiol.45, F476–F484.Suche in Google Scholar

Jozwiak, L., Drop, A., Buraczynska, K., Ksiazek, P., Mierzicki, P., and Buraczynska, M. (2004). Association of the human bradykinin B2 receptor gene with chromic renal failure. Mol. Diagn.8, 157–161.10.1007/BF03260059Suche in Google Scholar

Kitamura, N., Takagaki, Y., Furuto, S., Tanaka, T., Nawa, H., and Nakanishi, S. (1983). A single gene for bovine high molecular weight and low molecular weight kininogens. Nature305, 545–549.10.1038/305545a0Suche in Google Scholar

Kodama, K., Adachi, H., and Sonoda, J. (1997). Beneficial effects of long-term enalapril treatment and low-salt intake on survival rate of Dahl salt-sensitive rats with established hypertension. J. Pharmacol. Exp. Ther.283, 625–629.Suche in Google Scholar

Kraut, H., Frey, E.K., and Werle, E. (1930). Der Nachweis eines Kreislaufhormon in der Pankreasdrüse. Hoppe-Seyler's Z. Physiol. Chem.189, 97–106.10.1515/bchm2.1930.189.3-4.97Suche in Google Scholar

Lee-Chen, G.J., Liu, K.P., Lai, Y.C., Juang, H.S., Huang, S.Y., and Lin, C.Y. (2004). Significance of the tissue kallikrein promoter and transforming growth factor-β1 polymorphisms with renal progression in children with vesicoureteral reflux. Kidney Int.65, 1467–1472.10.1111/j.1523-1755.2004.00526.xSuche in Google Scholar

Linz, W. and Scholkens, B.A. (1992). Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol.20, S83–S90.Suche in Google Scholar

Liu, Y.H., Yang, X.P., Sharov, V.G., Nass, O., Sabbah, H.N., Peterson, E., and Carretero, O.A. (1997). Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J. Clin. Invest.99, 1926–1935.10.1172/JCI119360Suche in Google Scholar

Maestri, R., Milia, A.F., Salis, M.B., Graiani, G., Lagrasta, C., Monica, M., Corradi, D., Emanueli, C., and Madeddu, P. (2003). Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension41, 1151–1155.10.1161/01.HYP.0000064180.55222.DFSuche in Google Scholar

Majima, M., Mizogami, S., Kuribayashi, Y., Katori, M., and Ohishi, S. (1994). Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension24, 111–119.10.1161/01.HYP.24.1.111Suche in Google Scholar

Marceau, F. (1995). Kinin B1 receptors: a review. Immunopharmacology30, 1–26.10.1016/0162-3109(95)00011-HSuche in Google Scholar

Margolius, H.S. (1989). Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. Toxicol.29, 343–364.10.1146/annurev.pa.29.040189.002015Suche in Google Scholar PubMed

Margolius, H.S., Geller, R., Pisano, J.J., and Sjoerdsma, A. (1971). Altered urinary kallikrein excretion in human hypertension. Lancet2, 1063–1065.10.1016/S0140-6736(71)90382-5Suche in Google Scholar

Martorana, P.A., Kettenbach, B., Breipohl, G., Linz, W., and Scholkens, B.A. (1990). Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur. J. Pharmacol.182, 395–396.10.1016/0014-2999(90)90301-LSuche in Google Scholar

Medeiros, R., Cabrini, D.A., Ferreira, J., Fernandes, E.S., Mori, M.A., Pesquero, J.B., Bader, M., Avellar, M.C., Campos, M.M., and Calixto, J.B. (2004). Bradykinin B1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-κB signaling pathways. Circ Res.94, 1375–1382.10.1161/01.RES.0000128404.65887.08Suche in Google Scholar

Meneton, P., Bloch-Faure, M., Hagege, A.A., Ruetten, H., Huang, W., Bergaya, S., Ceiler, D., Gehring, D., Martins, I., Salmon, G., et al. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc. Natl. Acad. Sci. USA27, 2634–2639.10.1073/pnas.051619598Suche in Google Scholar

Miller, D.H., Chao, J., and Margolius, H.S. (1984). Tissue kallikrein synthesis and its modification by testosterone or low dietary sodium. Biochem. J.218, 37–43.10.1042/bj2180037Suche in Google Scholar

Montanari, D., Dobrzynski, E., Agata, J., Yoshida, H., Yin, H., Chao, J., and Chao, L. (2005). Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes54, 1573–1580.10.2337/diabetes.54.5.1573Suche in Google Scholar

Moreau, M.E., Garbacki, N., Molinaro, G., Brown, N.J., Marceau, F., and Adam, A. (2005). The kallikrein-kinin system: current and future pharmacological targets. J. Pharamcol. Sci.99, 6–38.10.1254/jphs.SRJ05001XSuche in Google Scholar

Movat, H.Z. (1979). The plasma kallikrein-kinin system and its interrelationship with other components of blood. In: Bradykinin, Kallidin and Kallikrein, E.G. Erdös, ed. (Berlin, Germany: Springer Verlag), pp. 1–89.10.1007/978-3-642-67301-6_1Suche in Google Scholar

Muller-Esterl, W. (1986). Kininogens revisited. Trends. Biochem. Sci.11, 336.10.1016/0968-0004(86)90293-8Suche in Google Scholar

Murakami, H., Yayama, K., Chao, L., and Chao, J. (1998). Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int.53, 1305–1313.10.1046/j.1523-1755.1998.00867.xSuche in Google Scholar PubMed

Murakami, H., Yayama, K., Miao, R.Q., Wang, C., Chao, L., and Chao, J. (1999a). Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension34, 164–170.10.1161/01.HYP.34.2.164Suche in Google Scholar

Murakami, H., Miao, R.Q., Chao, L., and Chao, J. (1999b). Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology44, 137–143.10.1016/S0162-3109(99)00120-4Suche in Google Scholar

Murray, S.R., Chao, J., Lin, F.K., and Chao, L. (1990). Kallikrein multigene families and the regulation of their expression. J. Cardiovasc. Pharmacol.15, S7–S16.Suche in Google Scholar

Naicker, S., Naidoo, S., Ramsaroop, R., Moodley, D., and Bhoola, K. (1999). Tissue kallikrein and kinins in renal disease. Immunopharmacology44, 183–192.10.1016/S0162-3109(99)00089-2Suche in Google Scholar

Nolly, H., Carbini, L.A., Scicli, G., Carretero, O.A., and Scicli, A.G. (1994). A local kallikrein-kinin system is present in rat hearts. Hypertension23, 919–923.10.1161/01.HYP.23.6.919Suche in Google Scholar

Okumura, H., Nagaya, N. Itoh, T., Okano, I., Hino, J., Mori, K., Tsukamoto, Y., Ishibashi-Ueda, H., Miwa, S., Tambara, K., Toyokuni, S., Yutani, C., and Kangawa, K. (2004). Adrenomedullin infusion attenuates myocardial I/R injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation109, 242–248.10.1161/01.CIR.0000109214.30211.7CSuche in Google Scholar

Ole-Moi Yoi, O., Seldin, O.C., Spagg, J., Pinkus, G., and Austen, K.F. (1979). Sequential cleavage of proinsulin by human pancreatic kallikrein and a human pancreatic kininase. Proc. Natl. Acad. Sci. USA76, 3612–3616.10.1073/pnas.76.8.3612Suche in Google Scholar

Overlack, A., Stumpe, K.O., Ressel, C., Kolloch, R., Zywzok, W., and Kruck, F. (1980). Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Klin. Wochenschr.58, 37–42.10.1007/BF01477142Suche in Google Scholar

Overlack, A., Stumpe, K.O., Kolloch, R., Ressel, C., and Krueck, F. (1981). Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension3, I18–I21.Suche in Google Scholar

Pan, Z.K., Zuraw, B.L., Lung, C.C., Prossnitz, E.R., Browning, D.D., and Ye, R.D. (1996). Bradykinin stimulates NF-κB activation and interleukin 1β gene expression in cultured human fibroblasts. J. Clin. Invest.98, 2042–2049.10.1172/JCI119009Suche in Google Scholar

Patel, R., McAndrew, J., Sellak, H., White, C., Jo, H., Freeman, B., and Darley-Usmar, V. (1999). Biological aspects of reactive nitrogen species. Biochim. Biophys. Acta141, 385–400.10.1016/S0005-2728(99)00028-6Suche in Google Scholar

Powers, C.A. (1983). A kininogenase resembling glandular kallikrein in the rat pituitary pars intermedia. Endocrinology112, 1194–1200.10.1210/endo-112-4-1194Suche in Google Scholar PubMed

Powers, C.A. (1986). Dopaminergic regulation of glandular kallikrein in the intermediate lobe of the rat pituitary. J. Neurochem.47, 145–154.10.1159/000124564Suche in Google Scholar

Pravenec, M., Kren, V., Kunes, J., Scicli, A.G., Carretero, O.A., Simonet, L., and Kurtz, T.W. (1991). Cosegregation of blood pressure with a kallikrein gene family. Hypertension17, 242–246.10.1161/01.HYP.17.2.242Suche in Google Scholar

Price, R.G. (1982). Urinary enzymes, nephrotoxicity and renal disease. Toxicology23, 99–134.10.1016/0300-483X(82)90092-0Suche in Google Scholar

Prichett, D.B. and Roberts, J.L. (1987). Dopamine regulates expression of the glandular-type kallikrein gene at the transcriptional level in the pituitary. Proc. Natl. Acad. Sci. USA84, 5545–5549.10.1073/pnas.84.16.5545Suche in Google Scholar

Regoli, D., Rhaleb, N.E., Drapeau, G., and Dion, S. (1990). Kinin receptor subtypes. J. Cardiovasc. Pharmacol.15, S30–S38.Suche in Google Scholar

Regoli, D., Gobeil, F., Nguyen, Q.T., Jukic, D., Seoane, P.R., Salvino, J.M., and Sawutz, D.G. (1994). Bradykinin receptor types and B2 subtypes. Life Sci.55, 735–749.10.1016/0024-3205(94)00557-5Suche in Google Scholar

Richer, C., Vacher, E., Fornes, P., and Giudicelli, J.F. (1997). Antihypertensive drugs in the stroke-prone spontaneously hypertensive rat. Clin. Exp. Hypertens.19, 925–936.10.3109/10641969709083196Suche in Google Scholar PubMed

Rosewicz, S., Detzen, K., Logsson, S.D., Chao, J., Chen, L., and Rieken, E.O. (1991). Effects of steroid hormones on glandular kallikrein gene expression in pancreatic AR42J cells. Endocrinology128, 2216–2222.10.1210/endo-128-5-2216Suche in Google Scholar PubMed

Schachter, M. (1956). A delayed slow contracting effect of serum and plasma due to the release of a substance resembling kallidin and bradykinin. Br. J. Pharmacol. Chemother.11, 111–118.10.1111/j.1476-5381.1956.tb01038.xSuche in Google Scholar PubMed PubMed Central

Schachter, M. (1979). Kallikreins (kininogenases) – a group of serine proteases with bioregulatory actions. Pharmacol. Rev.31, 1–17.Suche in Google Scholar

Schanstra, J.P., Neau, E., Drogoz, P., Gomez, M.A.A., Novoa, J.M.L., Calise, D., Pecher, C., Bader, M., Girolami, J.P., and Bascands, J.L. (2002). In vivo bradykinin B2 receptor activation reduces renal fibrosis. J. Clin. Invest.110, 371–379.10.1172/JCI0215493Suche in Google Scholar

Sealey, J., Atlas, S.A., Laragh, J.H., Oza, N.B., and Ryan, J.W. (1978). Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin. Nature275, 144–145.10.1038/275144a0Suche in Google Scholar PubMed

Sharma, J.N. and Sharma, J. (2002). Cardiovascular properties of the kallikrein-kinin system. Curr. Med. Res. Opin.18, 10–17.10.1185/03007990212500093Suche in Google Scholar PubMed

Silva, J.A. Jr., Araujo, R.C., Baltatu, O., Oliveira, S.M., Tschope, C., Fink, E., Hoffmann, S., Plehm, R., Chai, K.X., Chao, L., et al. (2000). Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J.14, 1858–1860.10.1096/fj.99-1010fjeSuche in Google Scholar PubMed

Song, Q., Chao, J., and Chao, L. (1996). High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin. Exp. Hypertens.18, 975–993.10.3109/10641969609081030Suche in Google Scholar PubMed

Souza, D.G., Pinho, V., Pesquero, J.L., Lomez, E.S., Poole, S., Juliano, L., Correa, A. Jr., de A. Castro, M.S., Teixeira, M.M. (2003). Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br. J. Pharmacol.139, 129–139.10.1038/sj.bjp.0705200Suche in Google Scholar PubMed PubMed Central

Souza, D.G, Lomez, E.S., Pinho, V., Pesquero, J.B., Bader, M., Pesquero, J.L., and Teixeira, M.M. (2004). Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J. Immunol.72, 2542–2548.10.4049/jimmunol.172.4.2542Suche in Google Scholar PubMed

Sterzel, R.B., Luft, F.C., Gao, Y., Schnermann, J., Briggs, J.P., Ganten, D., Waldherr, R., Schnabel, E., and Kriz, W. (1988). Renal disease and the development of hypertension in salt-sensitive Dahl rats. Kidney Int.33, 1119–1129.10.1038/ki.1988.120Suche in Google Scholar PubMed

Su, H., Joho, S., Huang, Y., Barcena, A., Arakawa-Hoyt, J., Grossman, W., and Kan, Y.W. (2004). Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc. Natl. Acad. Sci. USA101, 16280–16285.10.1073/pnas.0407449101Suche in Google Scholar PubMed PubMed Central

Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X.O., Logvinova, A., and Greenberg, D.A. (2003). VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest.111, 1843–1851.10.1172/JCI200317977Suche in Google Scholar

Takeda, Y., Yoneda, T., Demura, M., Furukawa, K., Miyamori, I., and Mabuchi, H. (2001). Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J. Hypertens.19, 635–639.10.1097/00004872-200103001-00017Suche in Google Scholar PubMed

Thongboonkerd, V., Gozal, E., Sachleben, L.R. Jr., Arthur, J.M., Pierce, W.M., Cai, J., Chao, J., Bader, M., Pesquero, J.B., Gozal, D., and Klein, J.B. (2002). Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J. Biol. Chem.277, 34708–34716.10.1074/jbc.M203799200Suche in Google Scholar PubMed

Tschope, C., Spillman, F., Rehfeld, U., Koch, M., Westermann, D., Altmann, C., Dendorfer, A., Walther, T., Bader, M., Paul, M., et al. (2004a). Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein gene. FASEB J.18, 1967–1969.10.1096/fj.04-1614fjeSuche in Google Scholar

Tschope, C., Walther, T., Koniger, J., Spillmann, F., Westermann, D., Escher, F., Pauschinger, M., Pesquero, J.B., Bader, M., Schultheiss, H.P., and Noutsias, M. (2004b). Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J.18, 828–835.10.1096/fj.03-0736comSuche in Google Scholar

Uehara, Y., Hirawa, N., Kawabata, Y., Suzuki, T., Ohshima, N., Oka, K., Ikeda, T., Goto, A., Toyooka, T., Kizuki, K., and Omata, M. (1994). Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension24, 770–778.10.1161/01.HYP.24.6.770Suche in Google Scholar

Vio, C.P. and Figueroa, C.D. (1987). Evidence for a stimulatory effect of high potassium diet on renal kallikrein. Kidney Int.31, 1327–1334.10.1038/ki.1987.146Suche in Google Scholar

Wang, J., Xiong, W., Yang, Z., Davis, T., Dewey, M.J., Chao, J., and Chao, L. (1994). Human tissue kallikrein induces hypotension in transgenic mice. Hypertension23, 236–243.10.1161/01.HYP.23.2.236Suche in Google Scholar

Wang, C., Chao, L., and Chao, J. (1995). Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest.95, 1710–1716.10.1172/JCI117847Suche in Google Scholar

Wang, D., Chao, J., and Chao, L. (1997). Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension29, 488–493.10.1161/01.HYP.29.1.488Suche in Google Scholar

Wang, C., Chao, C., Madeddu, P., Chao, L., and Chao, J. (1998). Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem. Biophys. Res. Commun.244, 449–454.10.1006/bbrc.1998.8232Suche in Google Scholar

Werle, E. (1960). Kallikrein, kallidin and related substance. In: Polypeptides which Affect Smooth Muscles and Blood Vessels. M. Schachter, ed. (Oxford, UK: Pergamon Press), pp. 199–209.Suche in Google Scholar

Werle, E., Gotz, W., and Kappler, A. (1937). Über die Wirkung des Kallikreins auf den isolierten Darm und über eine neue darmkontrahierende Substanz. Biochem. J.289, 217–233.Suche in Google Scholar

Wines, D.R., Brady, J.M. Pritchett, D.B., Roberts, J.L., and Macdonald, R.J. (1989). Organization and expression of the rat kallikrein gene family. J. Biol. Chem.264, 7653–7662.10.1016/S0021-9258(18)83284-7Suche in Google Scholar

Wolf, W.C., Yoshida, H., Agata, J., Chao, L., and Chao, J. (2000). Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int.58, 730–739.10.1046/j.1523-1755.2000.00219.xSuche in Google Scholar PubMed

Wong, C.M., O'Connor, D.T., Martinez, J.A., Kailasam, M.T., and Parmer, R.J. (2003). Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension. Am. J. Hypertens.16, 281–289.10.1016/S0895-7061(03)00002-5Suche in Google Scholar

Woodley-Miller, C., Chao, J., and Chao, L. (1989). Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J. Hypertens.7, 865–871.10.1097/00004872-198911000-00003Suche in Google Scholar

Xia, C.F., Yin, H., Borlongan, C.V., Chao, L., and Chao, J. (2004). Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension43, 452–459.10.1161/01.HYP.0000110905.29389.e5Suche in Google Scholar

Xia, C.F., Bledsoe, G., Chao, L., and Chao. J. (2005). Kallikrein gene transfer reduces renal fibrosis, hypertrophy and proliferation in deoxycorticosterone acetate-salt hypertensive rats. Am. J. Physiol. Renal Physiol.289, F622–F631.Suche in Google Scholar

Xia, C.F., Yin, H., Yao, Y.Y. Borlongan, C.V., Chao, L., and Chao, J. (2006a). Kallikrein/kinin protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene Ther.17, 206–219.10.1089/hum.2006.17.206Suche in Google Scholar

Xia, C.F., Smith, R., Shen, B., Borlongan, C., Chao, L., and Chao, J. (2006b). Post-ischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension47, 752–761.10.1161/01.HYP.0000214867.35632.0eSuche in Google Scholar

Xiong, W., Chao, J., and Chao, L. (1995). Muscle delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Hypertension25, 715–719.10.1161/01.HYP.25.4.715Suche in Google Scholar

Yang, H.Y.T., Erdos, E.G., and Levin, Y. (1970). A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim. Biophys. Acta14, 374–376.10.1016/0005-2795(70)90017-6Suche in Google Scholar

Yang, J., Dai, C., and Liu, Y. (2001a). Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther.8, 1470–1479.10.1038/sj.gt.3301545Suche in Google Scholar PubMed

Yang, S.W., Lee, W.K., Lee, E.J., Kim, K.Y., Lim, Y., Lee, K.H., Rha, H.K., and Hahn, T.W. (2001b). Effect of bradykinin on cultured bovine corneal endothelial cells. Ophthalmologica215, 303–308.10.1159/000050879Suche in Google Scholar PubMed

Yayama, K., Wang, C., Chao, L., and Chao, J. (1998). Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension31, 1104–1110.10.1161/01.HYP.31.5.1104Suche in Google Scholar PubMed

Yin, H., Chao, L., and Chao, J. (2005). Kallikrein-kinin protects against myocardial apoptosis after ischemia and reperfusion via activation of Akt-Bad-14-3-3 and Akt-GSK-3 signaling pathways. J. Biol. Chem.280, 8022–8030.10.1074/jbc.M407179200Suche in Google Scholar PubMed

Yoshida, H., Zhang, J.J., Chao, L., and Chao, J. (2000). Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension35, 25–31.10.1161/01.HYP.35.1.25Suche in Google Scholar

Yousef, G.M., Chang, A., Scorilas, A., and Diamandis, E.P. (2000). Genomic organization of the human kallikrein gene family on chromosome 19q13.3–q13.4. Biochem. Biophys. Res. Commun.276, 125–133.10.1006/bbrc.2000.3448Suche in Google Scholar PubMed

Yu, H., Song, Q., Freedman, B.I., Chao, J., Chao, L., Rich, S.S., and Bowden, D.W. (2002). Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int.61, 1030–1039.10.1046/j.1523-1755.2002.00198.xSuche in Google Scholar PubMed

Zhang, J.J., Chao, L., and Chao, J. (1999). Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke30, 1925–1931.10.1161/01.STR.30.9.1925Suche in Google Scholar PubMed

Zhang, J.J., Bledsoe, G., Kato, K., Chao, L., and Chao, J. (2004). Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int.66, 722–732.10.1111/j.1523-1755.2004.00794.xSuche in Google Scholar PubMed

Zhao, C., Wang, P., Xiao, X., Chao, J., Chao, L., Wang, D.W., and Zeldin, D.C. (2003). Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension42, 1026–1033.10.1161/01.HYP.0000097603.55404.35Suche in Google Scholar PubMed

Zhou, G.X., Chao, L., and Chao, J. (1992). Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J. Biol. Chem.267, 25873–25880.Suche in Google Scholar

Zinner, S.H., Margolius, H.S., Rosner, B., Keiser, H.R., and Kass, E.H. (1976). Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am. J. Epidemiol.104, 124–132.10.1093/oxfordjournals.aje.a112282Suche in Google Scholar PubMed

Zinner, S.H., Margolius, H.S., Rosner, B., and Kass, E.H. (1978). Stability of blood pressure rank and urinary kallikrein concentration in childhood. Circulation58, 908–915.10.1161/01.CIR.58.5.908Suche in Google Scholar

Published Online: 2006-06-26
Published in Print: 2006-06-01

©2006 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. The First International Symposium on Kallikreins
  2. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins
  3. The kallikrein world: an update on the human tissue kallikreins
  4. Cellular distribution of human tissue kallikreins: immunohistochemical localization
  5. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction
  6. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more
  7. Recombinant kallikrein expression: site-specific integration for hK6 production in human cells
  8. Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?
  9. The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition
  10. Human kallikrein 10, a predictive marker for breast cancer
  11. Activation and enzymatic characterization of recombinant human kallikrein 8
  12. Human tissue kallikrein 9: production of recombinant proteins and specific antibodies
  13. The human kallikrein 10 promoter contains a functional retinoid response element
  14. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins
  15. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum
  16. A sensitive proximity ligation assay for active PSA
  17. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer
  18. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues
  19. mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy
  20. The epigenetic basis for the aberrant expression of kallikreins in human cancers
  21. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network
  22. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells
  23. Inhibition profiles of human tissue kallikreins by serine protease inhibitors
  24. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs)
Heruntergeladen am 22.3.2026 von https://www.degruyterbrill.com/document/doi/10.1515/BC.2006.085/html?lang=de
Button zum nach oben scrollen